Synthesis, Pharmacological Properties, and Computational Study of 1-[3-(4-Aryl-1-piperazinyl)]propyl Derivatives of Amides of 7 Methyl-3-phenyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-5-carboxylic Acid

• Autorzy: Sabiniarz A. , Śladowska H. , Sapa J. , Filipek B. , Dudek M. , Godyń G. , Żyta J.
• Języki publikacji: EN

Abstrakty

EN

Two series of novel 1-[3-(4-aryl-1-piperazinyl)]- and 1-[2-hydroxy-3-(4-aryl-1- piperazinyl)]propyl derivatives of amides of 7-methyl-3-phenyl-2,4-dioxo- 1,2,3,4- tetrahydro - pyrido[2,3-d]pyrimidine-5-carboxylic acid (32–46) were synthesized. In the ”writhing syndrome” test all the amides studied displayed an algesic action. The most potent effect was produced by compounds 32, 34, and 46. In the ”hot plate” test only two amides, 34 and 37, showed strong an algesic activity. Further more, most of the investigated substances significantly suppressed spontaneous locomotor activity in mice and prolonged barbiturate sleep of these animals. QSAR analysis of the 14 new and 14 earlier described compounds was made.

Słowa kluczowe

EN

pyrido[2,3-d]pyrimidines; arylpiperazines; amides; analgesic activity; SAR; 2D-QSAR analysis; sedative

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Polish Journal of Chemistry
• Rocznik: 2009
• Tom: Vol. 83, nr 5
• Strony: 981--998
• Opis fizyczny: Bibliogr. 15 poz., rys.

Twórcy

autor

Sabiniarz A.

autor

Śladowska H.

autor

Sapa J.

autor

Filipek B.

autor

Dudek M.

autor

Godyń G.

autor

Żyta J.

• Department of Chemistry of Drugs, Wrocław University of Medicine, Tamka 1, 50-137 Wrocław, Poland,

Bibliografia

• 1. Damaj M.I, Glassco W, Aceto M.D. and Martin B.R., J. Pharmacol. Exp. Ther., 291, 390 (1999).
• 2. Sawynok J, Pharmacol. Rev., 55, 1 (2003).
• 3. Śladowska H., Sieklucka-Dziuba M, Rajtar G, Sadowski M. and KleinrokZ., Farmaco, 54,773(1999).
• 4. Śladowska H, Sabiniarz A, Filipek B, Kardasz M. and Maciąg D., Farmaco, 58, 25 (2003).
• 5. Sabiniarz A, Śladowska H, Filipek B, Sapa J, Dudek M. and Ślepokura K, Acta Pol. Pharm. - Drug Res., 64, 369 (2007).
• 6. Śladowska H, Sieklucka-Dziuba M, Rejdak R. and Kleinrok Z, Farmaco, 55, 6 (2000).
• 7. Pollard C.B., Lauter W.M. and Nuessle N.O., J. Org. Chem., 24, 764 (1959).
• 8. Ferrand G, Dumas H., Depin J. and Chavemac G, Eur. J. Med. Chem., 22, 337 (1987).
• 9. Caliendo G, DiCarlo R, Meli R, Perissurti E, Santagada V, Silipo C. and Vittoria A., Eur. J. Med. Chem.,2%, 969(1993).
• 10. Śladowska H, Filipek B, Szkatuła D., Sabiniarz A, Kardasz M., Potoczek J, Sieklucka-Dziuba M, Rajtar G, Kleinrok Z. and Lis T, Farmaco, 57, 897 (2002).
• 11. Litchfield J.T. and Wilcoxon F, J. Pharmacol. Exp. Ther., 96, 99 (1949).
• 12. Hendershot L.C. and Forsaith J, J. Pharmacol. Exp. Ther., 125, 237 (1959).
• 13. Eddy N.B. and Leimbach D., J. Pharmacol. Exp. Ther., 107, 385 (1953).
• 14. United States Patent Document. Vol. #4376771, htpp://chem.sis.nlm.nih.gov/chemidplus/(aspirin).
• 15. Nippon Yakurigaku Zasshi. Japan J. Pharmacol., 53, 56S (1957), htpp://chem.sis.nlm.nih.gov/chemidplus/(morphine).